Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 659 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antiretroviral Treatment Clear all
Completed Not applicable Interventional

The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens

NCT00152061
View directory record Official record
Conditions
HIV Infections
Interventions
3TC and FTC
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

NCT00006604
View directory record Official record
Conditions
HIV Infections
Interventions
ATV, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
91 Days to 21 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

NCT00326716
View directory record Official record
Conditions
HIV Infection
Interventions
Atazanavir + Ritonavir + Combivir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00000865
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 13 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

NCT02471430
View directory record Official record
Conditions
HIV Infection
Interventions
Panobinostat, Pegylated Interferon-alpha2a
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 7, 2026, 11:41 PM EDT
Recruiting Phase 1 Interventional

STARLITE for Unresectable High-Grade Gliomas

NCT06428045
View directory record Official record
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 7, 2026, 11:41 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05586581
View directory record Official record
Conditions
HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
Interventions
SV2A PET, TSPO PET
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

NCT00034866
View directory record Official record
Conditions
HIV Infections
Interventions
Protease inhibitor tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
50
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 7, 2026, 11:41 PM EDT
Completed No phase listed Observational

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

NCT00001103
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Menlo Park, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 7, 2026, 11:41 PM EDT
Terminated No phase listed Observational

A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment

NCT00001069
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

NCT01386970
View directory record Official record
Conditions
HIV
Interventions
zidovudine 300mg and lamivudine 150mg as Combivir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 7, 2026, 11:41 PM EDT
Completed No phase listed Observational

A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor

NCT00432783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00002380
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 13 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Study of Anti-HIV Therapy Intensification

NCT00034086
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People

NCT00864916
View directory record Official record
Conditions
HIV, Vascular Diseases, Cardiovascular Diseases, Atherosclerosis, HIV Infections
Interventions
Combination antiretroviral therapy (cART), Pentoxifylline, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

NCT04050371
View directory record Official record
Conditions
HIV Prevention, Transgender Health
Interventions
200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

NCT02478632
View directory record Official record
Conditions
HIV Infections
Interventions
Subjects do not receive study medication in this study 202094
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

NCT03331978
View directory record Official record
Conditions
HIV/AIDS
Interventions
Rise - Treatment Education
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01497899
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

NCT01928927
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Telmisartan
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Medications for Chronic HIV: Education and Collaboration

NCT01038076
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome, Medication Adherence
Interventions
MedCHEC Tablet Computer & Adherence Care
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

NCT04039217
View directory record Official record
Conditions
ART, HIV
Interventions
Biktarvy
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 7, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 7, 2026, 11:41 PM EDT